Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

hafiz caem

TipRanks

Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%

When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is taking the latter view.Despite the volatility that has ruled the market over the last few weeks, Stoltzfus actually likes what he’s witnessing in both the market and the economy. In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets… We’ve taken out the froth that had come into the market in certain [mega cap] names. It may be a good opportunity to pick up some really good, high quality growth stories that are

Read More

BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates

hafiz caem

– Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone-

– Completed PROTECTIVE-2 Phase 3 Enrollment and On Track to Report Final Results in Q4 2020 / Expect to Submit NDA for CIN to the FDA by End of 2020 –

– Triple Plinabulin I/O Combination Achieved 100 Percent Complete Response in PD-1 Non-responsive Animal Model; To Initiate Clinical Studies at MD Anderson in H2 2020 –

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today its financial results and provided an operational update for the three months ended June 30, 2020.

“BeyondSpring’s mission has been to develop innovative, transformative medicines that improve clinical outcomes in high unmet medical needs,” said Dr. Lan

Read More

Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020

hafiz caem

BASINGSTOKE, United Kingdom & MADISON, Wis.–(BUSINESS WIRE)–Genus plc (LSE: GNS), a world leading animal genetics company producing superior breeding livestock through genetic improvement, today announced that it will release its preliminary financial results for the full year ended June 30, 2020, and provide a business update on recent corporate developments in its worldwide porcine and bovine genetics businesses, on Tuesday, September 8, 2020.

Webcast Results Presentation

A pre-recorded briefing by management to discuss the preliminary results for the year ended June 30, 2020 will be held via a video webcast facility and will be accessible at the following link beginning at 7:01 AM BST, 1:01 AM EDT on September 8th: https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.

An archived recording of the webcast will also be available on the Investors section of the Company’s website.

About Genus

Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock

Read More

Immatics Announces Second Quarter 2020 Financial Results and Business Update

The MarketWatch News Department was not involved in the creation of this content.

Tuebingen, Germany and Houston, TX, Sep 03, 2020 (GLOBE NEWSWIRE via COMTEX) —
Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) —

  • Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction totaling $253 million (EUR226 million1) in July 2020.
  • At the closing of the transaction, cash and cash equivalents amounted to $322 million (EUR288 million1) enabling Immatics to fund operating expenses and capital expenditure requirements for at least 36 months.
  • Expanded ACTengine(R) clinical programs into Europe with first patient treated with genetically engineered T cell product candidate IMA202 in August 2020; regulatory approval by Paul-Ehrlich-Institute to begin phase I clinical trial with product candidate IMA203 in Germany and to open additional clinical trial sites in the EU.
  • Expanded leadership team with appointment of
Read More

Sequana Medical announces H1 2020 results and provides business update

  • POSEIDON – Implants in Canada continue; interim results expected H1 2021
  • RED DESERT – Implants continue; interim results expected Q4 2020
  • DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe
  • Continued growth in European commercial implants
  • Secured additional funding extending cash runway into H2 2021

Conference call with live webcast presentation today at 14:00 CEST / 08:00 am EST

GHENT, Belgium, Sept. 03, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2020 and its outlook for the remainder of the year and into 2021.

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “We have continued to make good progress towards key milestones in our

Read More

Apogee Enterprises to Report Fiscal 2021 Second Quarter Financial Results

Apogee Enterprises, Inc. (Nasdaq: APOG) will report its fiscal 2021 second quarter results on Thursday, September 17, 2020 before the market opens. The company will also host a conference call to discuss its financial results and provide a business update. This conference call will be webcast beginning at 8:00 a.m. Central Time, on September 17, 2020.

Access to the webcast will be available through the Investors section of the company’s website at https://www.apog.com/events-and-presentations. For those unable to listen to the live webcast, a replay will be available on the company’s website.

About Apogee Enterprises, Inc.

Apogee Enterprises, Inc. (Nasdaq: APOG) delivers distinctive solutions for enclosing commercial buildings and framing art. Headquartered in Minneapolis, MN, we are a leader in architectural products and services, providing architectural glass, aluminum framing systems and installation services for buildings, as well as value-added glass and acrylic for custom picture framing and displays. For more information,

Read More

iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update

– July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 –

– EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continue to progress in clinical trials –

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2020 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.

“The completion of our successful IPO in July was a major milestone for iTeos and further supports the advancement of our highly differentiated immunotherapy pipeline, including our two lead product candidates, our adenosine A2a receptor antagonist, EOS-850, and TIGIT antagonist, EOS-448,” said Michel Detheux, PhD, President and Chief Executive Officer of iTeos. “With trials ongoing for our two lead product candidates, we anticipate that 2021

Read More

Copart Reports Fourth Quarter Fiscal 2020 Financial Results

Copart, Inc. (NASDAQ: CPRT) today reported financial results for the quarter and year ended July 31, 2020.

For the three months ended July 31, 2020, revenue, gross profit, and net income were $525.7 million, $250.4 million, and $165.5 million, respectively. These represent a decrease in revenue of $16.9 million, or 3.1%; an increase in gross profit of $7.8 million, or 3.2%; and an increase in net income of $12.0 million, or 7.8%, respectively, from the same period last year. Fully diluted earnings per share for the three months ended July 31, 2020 were $0.69 compared to $0.64 last year, an increase of 7.8%.

For the year ended July 31, 2020, revenue, gross profit, and net income were $2.2 billion, $1.0 billion, and $699.9 million, respectively. These represent an increase in revenue of $163.6 million, or 8.0%; an increase in gross profit of $109.5 million, or 12.2%; and an increase in

Read More

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020

NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2020.

“I am pleased with the developments that were achieved during the first half of 2020 despite the challenges presented by the COVID-19 pandemic,” said Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group. “Throughout the COVID-19 crisis, we remained focused on advancing the development of our therapeutic programs. As announced today, further positive data showing significant in vivo activities of ALS-4 (for MRSA wound healing and MRSA bacteraemia) and also in vitro and in vivo studies of SACT-1 (for neuroblastoma and other potential tumor types). Also, as an emerging company, we have been expanding our global strategic

Read More

Fortress Technologies Inc. Announces Second Quarter 2020 Financial Results

The MarketWatch News Department was not involved in the creation of this content.

VANCOUVER, British Columbia, Aug 31, 2020 (GLOBE NEWSWIRE via COMTEX) —
VANCOUVER, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) — Fortress Technologies Inc. (“Fortress” or the “Company“) (TSXV: FORT), a well-capitalized company currently evaluating emerging opportunities in technology sectors, reports its results of operations for the second quarter and six months period ended June 30, 2020 (“Q2 2020“). For the full condensed consolidated interim financial statements and management discussion & analysis for the Q2 2020, please visit the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com.

Six-Months Ended June 30, 2020

“We are pleased to report revenue of $572,046 and net income of $95,188 for the first six months of 2020,” said Aydin Kilic, CEO of Fortress.

“Fortress is in a strong financial

Read More